Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Tax Provisions (2019 - 2025)

Historic Tax Provisions for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Q3 2025 value amounting to $18.3 million.

  • Catalyst Pharmaceuticals' Tax Provisions rose 3701.67% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.7 million, marking a year-over-year increase of 1877.96%. This contributed to the annual value of $52.9 million for FY2024, which is 5118.23% up from last year.
  • Catalyst Pharmaceuticals' Tax Provisions amounted to $18.3 million in Q3 2025, which was up 3701.67% from $17.2 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Tax Provisions' 5-year high stood at $23.7 million during Q4 2023, with a 5-year trough of -$7.3 million in Q3 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' median Tax Provisions value was $7.5 million (recorded in 2022), while the average stood at $9.1 million.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Tax Provisions skyrocketed by 50668.84% in 2021 and then tumbled by 32267.57% in 2023.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Tax Provisions stood at $3.5 million in 2021, then skyrocketed by 115.1% to $7.5 million in 2022, then soared by 214.94% to $23.7 million in 2023, then decreased by 21.02% to $18.7 million in 2024, then fell by 2.64% to $18.3 million in 2025.
  • Its last three reported values are $18.3 million in Q3 2025, $17.2 million for Q2 2025, and $14.5 million during Q1 2025.